Related Experiment Video
Updated: Aug 14, 2026
07:49
A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
Prazosin in hypertension with heart failure
Journal of Cardiovascular Pharmacology
|November 1, 1979
Summary
Prazosin, combined with diuretics, effectively lowered blood pressure and heart rate in patients with hypertensive heart failure. This combination therapy also improved cardiac function, offering a safe treatment option.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertensive heart failure presents a complex clinical challenge, requiring management of both elevated blood pressure and impaired cardiac function.
- Diuretic agents are standard therapy for fluid management in heart failure, but their efficacy in addressing the hypertensive component can be limited.
Purpose of the Study:
- To evaluate the efficacy and safety of prazosin in combination with diuretic agents (furosemide and polythiazide) for treating patients with hypertensive heart failure.
Main Methods:
- A study involving 11 patients diagnosed with hypertensive heart failure.
- Patients received daily doses of prazosin ranging from 6 to 16 mg, alongside furosemide and polythiazide.
- Cardiac function indices, including ejection fraction and ejection time, were monitored.
Main Results:
- Significant reductions in both supine and standing blood pressures were observed, from an average of 180/108 mmHg and 171/106 mmHg to 130/84 mmHg and 135/86 mmHg, respectively.
- Average heart rate decreased in both supine and standing positions.
- Improvements in left ventricular function were indicated by changes in cardiac function indices.
Conclusions:
- Prazosin, when used concurrently with diuretic agents, demonstrates significant efficacy in managing hypertensive heart failure.
- This combination therapy effectively reduces blood pressure and heart rate while improving cardiac function.
- The treatment regimen showed a favorable side effect profile, suggesting its utility for simultaneous management of heart failure and hypertension.
Related Concept Videos
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...